Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases

被引：20

作者：

Pinter, Andreas ^{[1
]}

Wilsmann-Theis, Dagmar ^{[2
]}

Peitsch, Wiebke K. ^{[3
]}

Moessner, Rotraut ^{[4
]}

机构：

[1] Univ Hosp Frankfurt Main, Dept Dermatol Venereol & Allergol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany

[2] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany

[3] Vivantes Klinikum Friedrichshain, Dept Dermatol & Phlebol, Berlin, Germany

[4] Univ Clin Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany

来源：

JOURNAL OF DERMATOLOGY | 2019年 / 46卷 / 05期

基金：

澳大利亚研究理事会;

关键词：

brodalumab; interleukin-17; A; interleukin-17 receptor A; palmoplantar pustular psoriasis; pustulosis palmoplantaris; PLAQUE PSORIASIS; EFFICACY; SAFETY; IXEKIZUMAB;

D O I：

10.1111/1346-8138.14815

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Palmoplantar pustular psoriasis, also termed palmoplantar pustulosis (PPP), is a rare disease affecting the palmoplantar regions characterized by sterile, yellow to brown pustules mostly on erythematous skin. PPP is related to a high burden due to painful, impaired and stigmatizing character. Several isoforms of interleukin (IL) have been implicated in its pathophysiology. Here, we report on four patients with PPP treated with the novel IL-17 receptor A blocker brodalumab, in whom this therapy was not successful or showed moderate improvement combined with adverse events.

引用

页码：426 / 430

页数：5